Summary
This prediction ended on 22.01.10 with a price of €1.93. The price of Evotec SE has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.06%. dimontalban has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 0.518% | 0.518% | -41.789% | -72.004% |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by dimontalban for this prediction
In the thread Evotec AG diskutieren
wo bleibt der Ausbruch
nach der Verlängerung der Zusammenarbeit mit der CHDI sollten weiter Milestone Zahlungen fliessen aber vor alklem neue Aufträge kommen. Vielleicht die Chance den Seitwärtskanal zu verlassen?